Læknablaðið - 15.01.2008, Qupperneq 25

FRÆÐIGREINAR
INFLÚENSULYF
Impact of oseltamivir treatment on influenza-related lower
respiratory tract complications and hospitalizations. Arch
Intem Med 2003; 163:1667-72.
17. Monto AS, Webster A, Keene O. Randomized, placebo-
controlled studies of inhaled zanamivir in the treatment of
influenza A and B: pooled efficacy analysis. J Antimicrob
Chemother 1999; 44 Suppl B: 23-9.
18. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG.
Impact of zanamivir on antibiotic use for respiratory events
following acute influenza in adolescents and adults. Arch
Intern Med 2000; 160: 3234-40.
19. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Jr.,
Elliott MJ, Crisp A. Zanamivir in the prevention of influenza
among healthy adults: a randomized controlled trial. JAMA
1999; 282: 31-5.
20. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a
significant reduction in viral load during treatment in
military conscripts with influenza. Scand J Infect Dis 2003; 35:
52-8.
21. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration
of oral oseltamivir increases the benefits of influenza
treatment. J Antimicrob Chemother 2003; 51:123-9.
22. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey
EK. Safety and efficacy of the neuraminidase inhibitor GG167
in experimental human influenza. JAMA1996; 275: 295-9.
23. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and
safety of the neuraminidase inhibitor zanamivir in the
treatment of influenzavirus infections. GG167 Influenza
Study Group. N Engl J Med 1997; 337: 874-80.
24. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir
treatment of influenza in children. Pediatr Infect Dis J 2001;
20:127-33.
25. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding
in children with influenza virus infections treated with
neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24: 931-2.
26. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during
influenza outbreaks in Ontario nursing homes, 1999-2000. J
Am Geriatr Soc 2002; 50: 608-16.
27. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia
and other complications of influenza-like illness in patients
treated with oseltamivir. Curr Med Res Opin 2005; 21: 761-8.
28. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Tumer D,
Nicholson KG. Effectiveness of neuraminidase inhibitors in
treatment and prevention of influenza A and B: systematic
review and meta-analyses of randomised controlled trials.
BMJ 2003; 326:1235.
29. Tumer D, Wailoo A, Nicholson K, Cooper N, Sutton A,
Abrams K. Systematic review and economic decision
modelling for the prevention and treatment of influenza A
and B. Health Technol Assess 2003; 7: iii-iv, xi-xiii, 1-170.
30. Chik KW, Li CK, Chan PK, et al. Oseltamivir prophylaxis
during the influenza season in a paediatric cancer centre:
prospective observational study. Hong Kong Med J 2004; 10:
103-6.
31. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir
for the prevention of influenza in families. Zanamivir Family
Study Group. N Engl J Med 2000; 343:1282-9.
32. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir
prophylaxis: an effective strategy for the prevention of
influenza types A and B within households. J Infect Dis 2002;
186:1582-8.
33. Hayden FG, Belshe R, Villanueva C, et al. Management
of influenza in households: a prospective, randomized
comparison of oseltamivir treatment with or without
postexposure prophylaxis. J Infect Dis 2004; 189: 440-9.
34. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of
oseltamivir in preventing influenza in household contacts: a
randomized controlled trial. JAMA 2001; 285: 748-54.
35. Halloran ME, Hayden FG, Yang Y, Longini IM, Jr., Monto
AS. Antiviral effects on influenza viral transmission and
pathogenicity: observations from household-based trials. Am
J Epidemiol 2007; 165: 212-21.
36. Organization CSalR, CSIRO based dmg effective against bird
flu. www.csiro.au/
37. Trampuz A, Prabhu RM, Smith TF, Baddour LM. Avian
influenza: a new pandemic threat?(erratum appears in Mayo
Clin Proc 2004; 79: 833). Mayo Clinic Proceedings 2004; 79:
523-30; quiz 30.
38. de Jong MD, Tran TT, Tmong HK, et al. Oseltamivir
resistance during treatment of influenza A (H5N1) infection.
N Engl J Med 2005; 353: 2667-72.
39. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1)
infection in humans. N Engl J Med 2005; 353:1374-85.
40. Roberts NA. Treatment of influenza with neuraminidase
inhibitors: virological implications. Philosophical transactions
of the Royal Society of London 2001; 356:1895-7.
41. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant
influenza A vimses in children treated with oseltamivir:
descriptive study. Lancet 2004; 364: 759-65.
42. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir
(Tamiflu) and its potential for use in the event of an influenza
pandemic. J Antimicrob Chemother 2005; 55 Suppl 1: Í5-Í21.
43. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in
the influenza A/HINI neuraminidase active site following
oseltamivir phosphate treatment leave vims severely
compromised both in vitro and in vivo. Antiviral Res 2002;
55: 307-17.
44. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of dmg-
resistant H5N1 vims. Nature 2005; 437:1108.
45. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of
antiviral-resistant influenza vimses to novel neuraminidase
inhibitors. Antimicrob Agents Chemother 2005; 49: 4515-20.
46. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of
neuraminidase enzyme assays using different substrates
to measure susceptibility of influenza vims clinical isolates
to neuraminidase inhibitors: report of the neuraminidase
inhibitor susceptibility network. J Clin Microbiol 2003; 41:
742-50.
47. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P.
Safety and pharmacology of oseltamivir in clinical use. Drug
safety 2003; 26: 787-801.
48. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and
safety of oseltamivir in treatment of acute influenza: a
randomised controlled trial. Neuraminidase Inhibitor Flu
Treatment Investigator Group. Lancet 2000; 355:1845-50.
49. Oseltamivir: cutaneous and neurological adverse effects in
children. Prescrire intemational 2006; 15:182-3.
50. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and
delirious behavior in children with influenza. Pediatr Infect
Dis J 2006; 25: 572.
51. Henney JE. From the food and dmg administration: revised
labeling for zanamivir. 2000; 284:1234.
52. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Tumer D,
Nicholson KG. Effectiveness of neuraminidase inhibitors in
treatment and prevention of influenza A and B: systematic
review and meta-analyses of randomised controlled trials.
BMJ 2003; 326:1235.
53. www.who.int/csr/disease/avian_influenza/timeline2007_
06_21.pdf.
54. www.who.int/csr/disease/avian_influenza/country/en/
55. Schunemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice
Guidelines for pharmacological management of sporadic
human infection with avian influenza A (H5N1) vims. Lancet
Infect Dis 2007; 7: 21-31.
56. Leiðbeiningar til starfsmanna á alifuglabúum og þeirra
sem sjá um förgun fugla og annarra dýra sem sýkt eru af
skæðri fuglainflúensu. (www.landlaeknir.is/lisalib/getfile.
aspx?itemid=3024.
57. www.who.int/csr/disease/avian_influenza/guidelines/
clinicalmanage07/en/index.html.
58. Tang JW, Li Y, Eames I, Chan PK, Ridgway GL. Factors
involved in the aerosol transmission of infection and control
of ventilation in healthcare premises. J Hosp Infect 2006; 64:
100-14.
59. www.pandemicflu.gov/plan/healthcare/maskguidancehc.
html.
60. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC,
Burke DS. Strategies for mitigating an influenza pandemic.
Nature 2006; 442: 448-52.
61. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies
for containing an emerging influenza pandemic in Southeast
Asia. Nature 2005; 437: 209-14.
LÆKNAblaðið 2008/94 25